Nomura Holdings’s BioXcel Therapeutics BTAI Stock Holding History

Nomura Holdings’s Portfolio BTAI Stock Details BTAI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-4,875	Closed	-$519K	–	1392
2023 Q2	$519K	Buy	+4,875	New	+$1.62M	﹤0.01%	1041

Other funds holding BTAI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BPA

Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Nomura Holdings's BTAI Position: Q3 2023 in Review

Nomura Holdings sold out of BioXcel Therapeutics (BTAI) in Q3 2023, closing a stake of 4,875 shares — an estimated $519K sold.

Nomura Holdings first reported a position in BTAI in Q2 2023 and held it in 1 quarter. The position peaked at $519K in Q2 2023. 85 funds tracked by Wall St. Rank hold BTAI as of Q3 2023.

Nomura Holdings reported no remaining BioXcel Therapeutics position as of Q3 2023 after selling out during the quarter.
Nomura Holdings sold 4,875 BioXcel Therapeutics shares in Q3 2023, an estimated $519K.
Nomura Holdings first reported a position in BioXcel Therapeutics in Q2 2023 and held it in 1 quarter.
Nomura Holdings's BioXcel Therapeutics position peaked at $519K in Q2 2023.
85 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q3 2023.

Based on Nomura Holdings's 13F filing for Q3 2023, filed 14 Nov 2023.